Home | Value-Based Cancer Care

Featured Content

Webinar Now Available - The Future of Accelerated Approval: Evolving to Better Serve Cancer Patients

On Demand Webinar is now available! The Future of Accelerated Approval: Evolving to Better Serve Cancer Patients was designed to foster a conversation on exploring opportunities to sustain early approval and access to treatments for patients with serious and life-threatening conditions.

View Content
Featured Video

The Future of Cancer Care Delivery

The future of cancer care delivery is shifting from fee-for-service to a value-based care approach.

View Content
Featured Article

Expert Insights on Innovation in the Oncology Pipeline

Total growth in the oncology pipeline in 2020 has been driven by targeted therapies, said Doug Long, Vice President, Industry Relations, IQVIA, at the 10th Annual Summit of the Association for Value-Based Cancer Care (AVBCC) in 2020.

View Content
Listen to our AVBCC Podcasts

Now you can take the Association for Value-Based Cancer Care (AVBCC) on the go with AVBCC podcasts. As healthcare professionals, it can be hard to find time in your busy schedule to stay up-to-date on oncology trends. Now you can receive trusted information from top industry leaders in an easy-to-listen format.

View Content

Top Trending Articles

1.

Zanubrutinib Superior to Ibrutinib in Patients with Relapsed or Refractory CLL/SLL

2.

Relapsed or Refractory FL: Best Practices for Active Surveillance & Reinforcement of Management Plans

Tycel J. Phillips, MD, Peg Rummel, MHA, RN, OCN, NE-BC, Andrew D. Zelenetz, MD, PhD

3.

Navigating Care Programs in the Post-OCM era

FDA Approvals, News & Updates

Orserdu FDA Approved for ER-Positive, Advanced or Metastatic Breast Cancer with ESR1 Mutation

Adstiladrin, First Adenoviral Vector–Based Gene Therapy, FDA Approved for High-Risk Non–Muscle Invasive Bladder Cancer

Krazati Receives Accelerated FDA Approval for NSCLC with KRASᴳ¹²ᶜ Mutation

View More Articles

Highlights from the Latest Issue: February 2023, Vol 14, No 1

February 2023, Vol 14, No 1

Krazati Receives Accelerated FDA Approval for NSCLC with KRASᴳ¹²ᶜ Mutation

Keytruda Received FDA Approval for Adjuvant Treatment of NSCLC

Tukysa, in Combination with Trastuzumab, Now FDA Approved for HER2-Positive, Unresectable or Metastatic Colorectal Cancer

Brukinsa Now FDA Approved for Patients with CLL or SLL

In the Literature

Low-Dose Capecitabine Maintenance Therapy Improves Survival in Patients with Triple-Negative Breast Cancer

Patients with triple-negative breast cancer (TNBC) have a high relapse rate and poor outcome after standard treatment. Capecitabine (Xeloda), a chemotherapy that has been used widely in the treatment of metastatic breast cancer, is a potential maintenance treatment option for the prevention of TNBC recurrence based on results of a recent study.

Quick Quiz: Chronic Myeloid Leukemia

Quick Quiz: Chronic Myeloid Leukemia

Chronic myeloid leukemia, also known as chronic myelogenous leukemia, is a malignancy that originates in blood-forming cells (called myeloid cells) found in bone marrow. How much do you know about chronic myeloid leukemia?

Value-Based Care

Breast Reconstruction Disparities Improve Significantly with Medicaid Expansion

Walter Alexander

Innovative Technology Supports Value-Based Care Success

Amy Valley, PharmD

The Alliance for Innovation in Integrated Healthcare Provides New Forum for Stakeholders

ASH 2020 Presidential Symposium Highlights Innovations Aimed to Improve Patient Access to Treatment

View More Articles

Personalized Medicine | Browse By Specialty

We Want to Know

Latest Videos

Navigating Care Programs in the Post-OCM era

Navigating Care Programs in the Post-OCM era

Tackling Health Equity in Oncology

Tackling Health Equity in Oncology

View More Videos

Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive:

VBCC Print Edition

VBCC Weekly e‑Newsletter

I have reviewed and consent to the terms of VBCC's Privacy Policy, and VBCC has my permission to retain my information in its database, and to forward pertinent communications to me.